Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com

Omeros (NASDAQ:OMER) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Thursday.

OMER has been the subject of a number of other research reports. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Omeros has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

NASDAQ OMER opened at $8.01 on Thursday. The firm’s 50 day moving average price is $8.90 and its 200-day moving average price is $7.12. Omeros has a 52-week low of $2.61 and a 52-week high of $13.60. The company has a market cap of $464.18 million, a PE ratio of -3.47 and a beta of 2.03.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Barclays PLC boosted its holdings in shares of Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 51,873 shares in the last quarter. State Street Corp raised its position in Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after purchasing an additional 3,839 shares during the last quarter. HighTower Advisors LLC raised its position in Omeros by 7.2% in the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 4,000 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Omeros in the 3rd quarter valued at $305,000. Finally, MML Investors Services LLC raised its position in Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.